BG64541B1 - Фармацевтични състави,съдържащи ламивудин и зидовудин, и използването им - Google Patents

Фармацевтични състави,съдържащи ламивудин и зидовудин, и използването им Download PDF

Info

Publication number
BG64541B1
BG64541B1 BG103435A BG10343599A BG64541B1 BG 64541 B1 BG64541 B1 BG 64541B1 BG 103435 A BG103435 A BG 103435A BG 10343599 A BG10343599 A BG 10343599A BG 64541 B1 BG64541 B1 BG 64541B1
Authority
BG
Bulgaria
Prior art keywords
pharmaceutically acceptable
pharmaceutical composition
lamivudine
zidovudine
amount
Prior art date
Application number
BG103435A
Other languages
Bulgarian (bg)
English (en)
Other versions
BG103435A (en
Inventor
Gary Goodson
Allen Wood
Katherine Ford
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Publication of BG103435A publication Critical patent/BG103435A/xx
Publication of BG64541B1 publication Critical patent/BG64541B1/bg

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • AIDS & HIV (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
BG103435A 1996-10-31 1999-05-26 Фармацевтични състави,съдържащи ламивудин и зидовудин, и използването им BG64541B1 (bg)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9622681.6A GB9622681D0 (en) 1996-10-31 1996-10-31 Pharmaceutical compositions

Publications (2)

Publication Number Publication Date
BG103435A BG103435A (en) 2000-04-28
BG64541B1 true BG64541B1 (bg) 2005-07-29

Family

ID=10802224

Family Applications (1)

Application Number Title Priority Date Filing Date
BG103435A BG64541B1 (bg) 1996-10-31 1999-05-26 Фармацевтични състави,съдържащи ламивудин и зидовудин, и използването им

Country Status (43)

Country Link
EP (1) EP0941100B1 (is)
JP (1) JP2001502718A (is)
KR (1) KR100551652B1 (is)
AP (1) AP1067A (is)
AR (1) AR009135A1 (is)
AT (1) ATE241364T1 (is)
AU (1) AU736607B2 (is)
BG (1) BG64541B1 (is)
BR (1) BR9712614A (is)
CA (1) CA2270174A1 (is)
CO (1) CO4930269A1 (is)
CY (1) CY2485B1 (is)
CZ (1) CZ296080B6 (is)
DE (1) DE69722433T2 (is)
DK (1) DK0941100T3 (is)
EA (1) EA002437B1 (is)
EE (1) EE03806B1 (is)
ES (1) ES2200204T3 (is)
GB (1) GB9622681D0 (is)
GE (1) GEP20022735B (is)
GT (1) GT199700116A (is)
HR (1) HRP970569B1 (is)
HU (1) HU224969B1 (is)
ID (1) ID18698A (is)
IL (1) IL129422A0 (is)
IS (1) IS5024A (is)
MY (1) MY119513A (is)
NO (1) NO317163B1 (is)
NZ (1) NZ335153A (is)
OA (1) OA11038A (is)
PA (1) PA8441101A1 (is)
PE (1) PE10099A1 (is)
PL (1) PL190349B1 (is)
PT (1) PT941100E (is)
SI (1) SI0941100T1 (is)
SK (1) SK284286B6 (is)
SV (1) SV1997000090A (is)
TR (1) TR199900950T2 (is)
UA (1) UA64725C2 (is)
UY (1) UY24766A1 (is)
WO (1) WO1998018477A2 (is)
YU (1) YU19999A (is)
ZA (1) ZA979726B (is)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9622681D0 (en) * 1996-10-31 1997-01-08 Glaxo Group Ltd Pharmaceutical compositions
GB9809213D0 (en) * 1998-04-29 1998-07-01 Glaxo Group Ltd Pharmaceutical compositions
US7074417B2 (en) * 2000-10-13 2006-07-11 Advancis Pharmaceutical Corporation Multiple-delayed release anti-viral product, use and formulation thereof
DE60219965T2 (de) * 2002-04-23 2008-01-17 Lupin Ltd., Mumbai Lang wirkende zusammensetzungen enthaltend zidovudine und/oder lamivudine
AU2003291457A1 (en) * 2002-11-08 2004-06-03 Glaxo Group Limited Pharmaceutical antiviral compositions
EA015145B1 (ru) 2003-01-14 2011-06-30 Джилид Сайэнс, Инк. Фармацевтическая композиция и пероральная фармацевтическая дозированная форма (варианты), проявляющие активность в отношении вич-инфекций, лечебный набор и таблетка и способ лечения или предотвращения симптомов или эффектов вич-инфекции
AR045841A1 (es) * 2004-09-28 2005-11-16 Richmond Sa Com Ind Y Financie Una composicion farmaceutica solida que comprende al tiazolil metil ester del acido [5s-(5r*, 8r*, 10r*,11r*)] -10- hidroxi-2- metil-5-(1-metiletil)-1-[2-(1-metiletil)-4-tiazolil]-3,6-dioxo-8,11-bis(fenilmetil)-2,4,7,12- tetraazatridecan-13-oico y un procedimiento para prepararla.
CN104203275A (zh) 2010-06-09 2014-12-10 疫苗技术股份有限公司 用于增强抗逆转录病毒治疗的hiv感染者的治疗性免疫
IN2014MN01907A (is) 2012-03-05 2015-07-10 Cipla Ltd
EP2958563A2 (en) * 2013-02-20 2015-12-30 AbbVie Inc. Tablet dosage form comprising ritonavir and lopinavir
JP2023010676A (ja) * 2021-07-09 2023-01-20 株式会社東洋新薬 固形組成物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4950652A (en) * 1987-03-23 1990-08-21 Hem Research, Inc. dsRNAs for combination therapy in the treatment of viral diseases
GB9110624D0 (en) * 1991-05-16 1991-07-03 Glaxo Group Ltd Combinations
DE69206876T3 (de) * 1991-05-16 2004-08-12 Glaxo Group Ltd., Greenford Nukleosidanalogen enthaltende Antiviren-Zubereitungen
GB9622681D0 (en) * 1996-10-31 1997-01-08 Glaxo Group Ltd Pharmaceutical compositions

Also Published As

Publication number Publication date
PL190349B1 (pl) 2005-11-30
SV1997000090A (es) 1998-10-07
OA11038A (en) 2002-02-06
NO317163B1 (no) 2004-08-30
HUP0000344A2 (hu) 2001-05-28
ID18698A (id) 1998-04-30
EE9900175A (et) 1999-12-15
GB9622681D0 (en) 1997-01-08
EE03806B1 (et) 2002-08-15
MY119513A (en) 2005-06-30
NO992091D0 (no) 1999-04-29
EA199900345A1 (ru) 2000-02-28
AP1067A (en) 2002-05-01
HRP970569B1 (en) 2004-10-31
HU224969B1 (en) 2006-04-28
GT199700116A (es) 1999-04-22
KR100551652B1 (ko) 2006-02-13
SI0941100T1 (en) 2003-12-31
CZ155799A3 (cs) 1999-10-13
AR009135A1 (es) 2000-03-08
CY2485B1 (en) 2005-06-03
AP9901519A0 (en) 1999-06-30
WO1998018477A2 (en) 1998-05-07
HK1020880A1 (en) 2000-05-26
HRP970569A2 (en) 1998-08-31
BR9712614A (pt) 1999-10-26
ZA979726B (en) 1999-04-29
JP2001502718A (ja) 2001-02-27
PT941100E (pt) 2003-10-31
GEP20022735B (en) 2002-07-25
CA2270174A1 (en) 1998-05-07
UY24766A1 (es) 2000-12-29
IS5024A (is) 1999-04-09
NZ335153A (en) 2001-04-27
EA002437B1 (ru) 2002-04-25
DE69722433D1 (de) 2003-07-03
ATE241364T1 (de) 2003-06-15
YU19999A (sh) 2000-10-30
PL333143A1 (en) 1999-11-22
BG103435A (en) 2000-04-28
IL129422A0 (en) 2000-02-17
PA8441101A1 (es) 2000-05-24
TR199900950T2 (xx) 1999-07-21
KR20000052893A (ko) 2000-08-25
DK0941100T3 (da) 2003-09-01
NO992091L (no) 1999-06-29
AU736607B2 (en) 2001-08-02
ES2200204T3 (es) 2004-03-01
HUP0000344A3 (en) 2002-04-29
SK57599A3 (en) 2000-06-12
WO1998018477A3 (en) 1998-06-18
EP0941100B1 (en) 2003-05-28
DE69722433T2 (de) 2004-04-08
CZ296080B6 (cs) 2006-01-11
EP0941100A2 (en) 1999-09-15
CO4930269A1 (es) 2000-06-27
PE10099A1 (es) 1999-03-02
AU5314298A (en) 1998-05-22
SK284286B6 (sk) 2005-01-03
UA64725C2 (uk) 2004-03-15

Similar Documents

Publication Publication Date Title
US6113920A (en) Pharmaceutical compositions
CA2330391A1 (en) Homogeneous pharmaceutical compositions comprising abacavir, lamivudine and zidovudine
AP1067A (en) Pharmaceutical compositions containing lamivudine and zidovudine.
KR20200070246A (ko) 이중층 제약 정제 제제
US20050171127A1 (en) Pharmaceutical compositions comprising abacavir and lamivudine
WO2022132676A1 (en) Mini-tablet dosage form of a viral terminase inhibitor and uses thereof
MXPA99004025A (en) Pharmaceutical compositions containing lamivudine and zidovudine
HK1020880B (en) Pharmaceutical compositions containing lamivudine and zidovudine
US20050113394A1 (en) Pharmaceutical compositions
MXPA00010498A (en) Homogeneous pharmaceutical compositions comprising abacavir, lamivudine and zidovudine
CN1241142A (zh) 含有拉米夫定和齐多夫定的药用组合物
CZ20003998A3 (cs) Farmaceutický prostředek
MX2008007776A (en) Pharmaceutical combination comprising nucleotide and nucleoside reverse transcriptase inhibitors (such as tenofovir and lamivudine) in different parts of the dosage unit